David Lebwohl
Impact in
- Hematology top 2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Oncology top 2%
- Cancer Treatment and Pharmacology
- Metal complexes synthesis and properties
Papers in
- Oncology 17
- Cancer Treatment and Pharmacology 12
- Colorectal Cancer Treatments and Studies 4
-
- Angiogenesis and VEGF in Cancer 5
- Cancer therapeutics and mechanisms 2
- Co-authors
- Renzo Canetta (4 shared papers)O M Rosen (2 shared papers)A Ullrich (1 shared paper)Thomas J. Dull (1 shared paper)Chao‐Kai Chou (1 shared paper)David Russell (1 shared paper)Roberto Gherzi (1 shared paper)Neal Rosen (4 shared papers)
- Journals
- Journal of Clinical Oncology (4 papers)Journal of Biological Chemistry (3 papers)European Journal of Cancer (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)New England Journal of Medicine (2 papers)
- Partner nations
- United StatesGermanySwitzerland
In The Last Decade
David Lebwohl
31 papers receiving 3.2k citations
David Lebwohl's Hit Papers
Peers
Comparison fields: 5 of 107
- Hematology 562
- Oncology 1.1k
- Genetics 306
- Molecular Biology 1.8k
- Cancer Research 360
Countries citing papers authored by David Lebwohl
This map shows the geographic impact of David Lebwohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Lebwohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Lebwohl more than expected).
Fields of papers citing papers by David Lebwohl
This network shows the impact of papers produced by David Lebwohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Lebwohl. The network helps show where David Lebwohl may publish in the future.
Co-authors
The 25 scholars most cited alongside David Lebwohl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical development of platinum complexes in cancer therapy: an historical perspective and an update Hit paper breakdown → | 1998 | 667 |
| 2 | Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. Hit paper breakdown → | 1987 | 560 |
| 3 | Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Hit paper breakdown → | 2004 | 528 |
| 4 | 2008 | 423 | |
| 5 | 1995 | 166 | |
| 6 | 2005 | 129 | |
| 7 | 2011 | 115 | |
| 8 | 2003 | 113 | |
| 9 | 2013 | 77 | |
| 10 | A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. | 1994 | 71 |
| 11 | 2005 | 48 | |
| 12 | 2005 | 48 | |
| 13 | CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy Hit paper breakdown → | 2024 | 41 |
| 14 | Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. | 1993 | 36 |
| 15 | 1999 | 32 | |
| 16 | 1995 | 27 | |
| 17 | Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. | 1996 | 26 |
| 18 | Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line. | 1994 | 26 |
| 19 | 1999 | 16 | |
| 20 | 1991 | 15 |
About David Lebwohl
David Lebwohl is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Dermatology, having authored 31 papers that have together received 3.2k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (12 papers), Angiogenesis and VEGF in Cancer (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Chemotherapy-related skin toxicity (4 papers), Cancer, Hypoxia, and Metabolism (3 papers), Advanced Breast Cancer Therapies (3 papers), Breast Cancer Treatment Studies (2 papers) and Cancer therapeutics and mechanisms (2 papers). The work is most often cited by research in Hematology (562 citations), Oncology (1.1k citations), Genetics (306 citations), Molecular Biology (1.8k citations) and Cancer Research (360 citations). David Lebwohl has collaborated with scholars based in United States, Germany and Switzerland. Frequent co-authors include Renzo Canetta, O M Rosen, A Ullrich, Thomas J. Dull, Chao‐Kai Chou, David Russell, Roberto Gherzi, Neal Rosen, Laura Sepp‐Lorenzino and Jennifer Clark. Their work appears in journals such as Journal of Clinical Oncology, Journal of Biological Chemistry, European Journal of Cancer, Cancer Chemotherapy and Pharmacology and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.